



## **Tiss'You** **Financial Overview – 2025 Final – December 31st**

During FY2025, Tiss'You SRL delivered an exceptional financial performance, confirming and exceeding the strong growth trajectory already visible at September 30th.

Revenues reached €5.11 million, driven by strong international sales, while EBITDA is €2.57 million, reflecting strong profitability and operational leverage. Net profit reached €2.13 million, marking a record year for the company.

### **Growth Drivers**

- **International Expansion:** Export sales remained the main driver of growth, with strong traction across international markets.
- **Operational Leverage:** The company converted revenue growth into high profitability, with a strong EBITDA margin (50,3%).
- **Innovation Pipeline:** Continued investments in R&D, patents, product development, and regulatory activities strengthened Tiss'You's positioning in regenerative medicine.
- **Industrial Scale-Up:** The San Marino facility supported increasing production volumes and operational consolidation.

### **Outlook**

The 2025 results confirm Tiss'You as a fast-growing, profitable, and financially sound company in the regenerative medicine sector. The company enters 2026 with strong momentum, focusing on further international expansion, MDR certification progress, production scale-up, and continued development of next-generation regenerative products.

**Tiss'You SRL**

**Dr. Paolo Fattori, PhD**

Handwritten signature of Dr. Paolo Fattori, with the title 'CEO' written next to it.